

Valentina Fanotto

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6924661/publications.pdf>

Version: 2024-02-01

50
papers

1,062
citations

471509

17
h-index

414414

32
g-index

54
all docs

54
docs citations

54
times ranked

2179
citing authors

#	ARTICLE	IF	CITATIONS
1	Prognostic role of visceral fat for overall survival in metastatic colorectal cancer: A pilot study. <i>Clinical Nutrition</i> , 2021, 40, 286-294.	5.0	17
2	LDH as prognostic factor in second line treatment for advanced gastric cancer: The LINE study.. <i>Journal of Clinical Oncology</i> , 2021, 39, e16102-e16102.	1.6	1
3	A rapid, simple and sensitive LC-MS/MS method for lenvatinib quantification in human plasma for therapeutic drug monitoring. <i>PLoS ONE</i> , 2021, 16, e0259137.	2.5	7
4	The MIMIC Study: Prognostic Role and Cutoff Definition of Monocyte-to-Lymphocyte Ratio and Lactate Dehydrogenase Levels in Metastatic Colorectal Cancer. <i>Oncologist</i> , 2020, 25, 661-668.	3.7	21
5	P-246 Taxane cross-resistance: An exploratory analysis of second-line chemotherapy for metastatic gastric cancer. <i>Annals of Oncology</i> , 2020, 31, S170.	1.2	0
6	Epstein-Barr virus BART microRNAs in EBV- associated Hodgkin lymphoma and gastric cancer. <i>Infectious Agents and Cancer</i> , 2020, 15, 42.	2.6	29
7	Clinico-radiological monitoring strategies in patients with metastatic breast cancer: a real-world study. <i>Future Oncology</i> , 2020, 16, 2059-2073.	2.4	2
8	Biologically driven cut-off definition of lymphocyte ratios in metastatic breast cancer and association with exosomal subpopulations and prognosis. <i>Scientific Reports</i> , 2020, 10, 7010.	3.3	18
9	PIK3CA mutation in metastatic colorectal cancer (mCRC): Association with clinico-pathological features and outcome. <i>Annals of Oncology</i> , 2019, 30, v238.	1.2	0
10	Gastric cancer: Translating novels concepts into clinical practice. <i>Cancer Treatment Reviews</i> , 2019, 79, 101889.	7.7	60
11	Lactate Dehydrogenase (LDH) Response to First-Line Treatment Predicts Survival in Metastatic Breast Cancer: First Clues for A Cost-Effective and Dynamic Biomarker. <i>Cancers</i> , 2019, 11, 1243.	3.7	40
12	New Agents in the Treatment of Advanced Gastric Cancer: Targeted Therapy and Immunotherapy. <i>Current Clinical Pathology</i> , 2019, , 121-132.	0.0	0
13	Serum Biomarkers in Gastric Cancer. <i>Current Clinical Pathology</i> , 2019, , 107-117.	0.0	0
14	The <sc>IMPACT</sc> study: early loss of skeletal muscle mass in advanced pancreatic cancer patients. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2019, 10, 368-377.	7.3	61
15	Second-line treatment efficacy and toxicity in older vs. non-older patients with advanced gastric cancer: A multicentre real-world study. <i>Journal of Geriatric Oncology</i> , 2019, 10, 591-597.	1.0	6
16	Post-neoadjuvant strategies in breast cancer: From risk assessment to treatment escalation. <i>Cancer Treatment Reviews</i> , 2019, 72, 7-14.	7.7	25
17	Controversies in monitoring metastatic breast cancer during systemic treatment. Results of a GIM (Gruppo Italiano Mammella) survey. <i>Breast</i> , 2018, 40, 45-52.	2.2	4
18	Determinants of Last-line Treatment in Metastatic Breast Cancer. <i>Clinical Breast Cancer</i> , 2018, 18, 205-213.	2.4	8

#	ARTICLE	IF	CITATIONS
19	Estimating Survival Probabilities of Advanced Gastric Cancer Patients in the Second-Line Setting: The Gastric Life Nomogram. <i>Oncology</i> , 2018, 95, 344-352.	1.9	11
20	Prognostic role of alkaline phosphatase (ALP) and lactate dehydrogenase (LDH) in metastatic breast cancer (MBC) patients: First clues for cost-effective biomarkers.. <i>Journal of Clinical Oncology</i> , 2018, 36, e13079-e13079.	1.6	2
21	Pertuzumab and breast cancer: another piece in the anti-HER2 puzzle. <i>Expert Opinion on Biological Therapy</i> , 2017, 17, 365-374.	3.1	27
22	Sarcopenia in gastric cancer: when the loss costs too much. <i>Gastric Cancer</i> , 2017, 20, 563-572.	5.3	47
23	Immunotherapy for colorectal cancer: where are we heading?. <i>Expert Opinion on Biological Therapy</i> , 2017, 17, 709-721.	3.1	85
24	Immunotherapy for gastric cancers: emerging role and future perspectives. <i>Expert Review of Clinical Pharmacology</i> , 2017, 10, 609-619.	3.1	33
25	Prognostic factors in 868 advanced gastric cancer patients treated with second-line chemotherapy in the real world. <i>Gastric Cancer</i> , 2017, 20, 825-833.	5.3	32
26	Selecting patients for gastrectomy in metastatic esophago-gastric cancer: clinics and pathology are not enough. <i>Future Oncology</i> , 2017, 13, 2265-2275.	2.4	10
27	Outcomes of Advanced Gastric Cancer Patients Treated with at Least Three Lines of Systemic Chemotherapy. <i>Oncologist</i> , 2017, 22, 1463-1469.	3.7	27
28	New Frontiers in the Pathobiology and Treatment of Cancer Regimen-Related Mucosal Injury. <i>Frontiers in Pharmacology</i> , 2017, 8, 354.	3.5	165
29	Estimation of 12-weeks life expectancy in patients (pts) with metastatic gastric cancer (mGC) candidated for second-line treatment: the "Gastric Life" nomogram. <i>Annals of Oncology</i> , 2017, 28, vi46-vi47.	1.2	0
30	Second-line treatment efficacy in elderly vs. non-elderly advanced gastric cancer patients: an Italian multicentre real-world study. <i>Annals of Oncology</i> , 2017, 28, vi45.	1.2	0
31	Molecular classifications of gastric cancers: Novel insights and possible future applications. <i>World Journal of Gastrointestinal Oncology</i> , 2017, 9, 194.	2.0	46
32	Determinants of adjuvant chemotherapy use in small luminal-like breast cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, e12010-e12010.	1.6	0
33	Preliminary results from CAMEO-PRO study: Complementary and alternative medicine in oncology"Physicians inform oncological patients.. <i>Journal of Clinical Oncology</i> , 2017, 35, e21632-e21632.	1.6	0
34	HER-2 inhibition in gastric and colorectal cancers: tangible achievements, novel acquisitions and future perspectives. <i>Oncotarget</i> , 2016, 7, 69060-69074.	1.8	29
35	Do platinum salts fit all triple negative breast cancers?. <i>Cancer Treatment Reviews</i> , 2016, 48, 34-41.	7.7	46
36	FOLFOXIRI plus bevacizumab (bev) followed by maintenance with bev alone or bev plus metronomic chemotherapy (metroCT) in metastatic colorectal cancer (mCRC): The phase II randomized MOMA trial. <i>Annals of Oncology</i> , 2016, 27, vi560.	1.2	7

#	ARTICLE	IF	CITATIONS
37	May mutational status influence the metastatic pattern of colorectal cancer patients?. Annals of Oncology, 2016, 27, iv42.	1.2	0
38	Last-line treatment of luminal metastatic breast cancer: which factors influence the therapeutic choice?. Annals of Oncology, 2016, 27, iv63.	1.2	0
39	Treatment strategies in patients with Metastatic Breast Cancer: real-world practice in the United Kingdom (UK) and Italy. Annals of Oncology, 2016, 27, iv63.	1.2	0
40	Apatinib for gastric cancer: are we moving the antiangiogenic strategy any forward?. Translational Cancer Research, 2016, 5, S765-S771.	1.0	2
41	Abstract P2-08-06: Usefulness of the pre-treatment neutrophil-to-lymphocyte ratio in predicting first-line progression free-survival in triple-negative breast cancer patients. , 2016, , .		0
42	Prognostic factors in 868 advanced gastric cancer patients exposed to second-line therapy.. Journal of Clinical Oncology, 2016, 34, e15553-e15553.	1.6	0
43	1227 Risk of unplanned presentations and hospital admission of breast cancer outpatients. European Journal of Cancer, 2015, 51, S182.	2.8	0
44	2357 Prognostic factors in 709 advanced gastric cancer patients exposed to second-line therapy. European Journal of Cancer, 2015, 51, S454-S455.	2.8	0
45	2153 Analysis of the molecular profile of brain metastases from colorectal cancer and concordance with matched primary tumors. European Journal of Cancer, 2015, 51, S384-S385.	2.8	1
46	1860 Last-line treatment of advanced breast cancer: Which clinical characteristics may predict the outcome?. European Journal of Cancer, 2015, 51, S285.	2.8	0
47	Pattern of metastasis and outcome in patients with breast cancer. Clinical and Experimental Metastasis, 2015, 32, 125-133.	3.3	144
48	Skeletal metastases from breast cancer: pathogenesis of bone tropism and treatment strategy. Clinical and Experimental Metastasis, 2015, 32, 819-833.	3.3	28
49	Treatment during the last month of life in advanced cancer patients.. Journal of Clinical Oncology, 2015, 33, e17649-e17649.	1.6	0
50	Pattern of metastatic spread and prognosis of breast cancer biologic subtypes.. Journal of Clinical Oncology, 2014, 32, e12532-e12532.	1.6	9